characteristics.text: ERC000011
characteristics.characteristic: ENA-CHECKLIST
characteristics.text: 2023-08-27T20:22:31Z
characteristics.characteristic: ENA-FIRST-PUBLIC
characteristics.text: 2023-08-27T20:22:31Z
characteristics.characteristic: ENA-LAST-UPDATE
characteristics.text: SAMEA112484462
characteristics.characteristic: External Id
characteristics.text: Department of Life Science and Medecine
characteristics.characteristic: INSDC center name
characteristics.text: 2023-08-27T20:22:31Z
characteristics.characteristic: INSDC first public
characteristics.text: 2023-08-27T20:22:31Z
characteristics.characteristic: INSDC last update
characteristics.text: public
characteristics.characteristic: INSDC status
characteristics.text: ERS14601809
characteristics.characteristic: SRA accession
characteristics.text: S21/
characteristics.characteristic: Submitter Id
characteristics.text: batch_2
characteristics.characteristic: batch
characteristics.text: SKMEL30
characteristics.characteristic: cell_line
characteristics.text: Melanoma
characteristics.characteristic: cell_type
characteristics.text: human
characteristics.characteristic: common name
characteristics.text: NRAS mutant melanoma cell line SKMEL30 treated with CDK4/6i (Palbociclib) 1?M and MEKi (Bnimetinib) 16 nM for 14 days
characteristics.characteristic: description
characteristics.text: CDK4/6i (Palbociclib) 1?M, MEKi (Bnimetinib) 35 nM
characteristics.characteristic: inhibitors
characteristics.text: Homo sapiens
characteristics.characteristic: organism
characteristics.text: Homo sapiens
characteristics.characteristic: scientific_name
characteristics.text: Male
characteristics.characteristic: sex
characteristics.text: Day14
characteristics.characteristic: time of treatment
characteristics.text: SK_D14_3
characteristics.characteristic: title